Expert Discusses Fractionated Dose 177Lu-PSMA-617 in mCRPC
Scott T. Tagawa, MD, MS, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-PresbyterianWeill Cornell Medical Center, discusses fractionated dose 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).
Investigators are currently evaluating 177Lu-PSMA-617 in a dose-escalation study to determine the highest tolerable dose of the drug in patients with progressive mCRPC. So far, the phase I trial has not shown any significant acute or dose-limiting toxicities, says Tagawa. The low-grade toxicities observed were dry mouth and nausea, which were seen in other the prospective phase II study from Australia.
Tucatinib Plus T-DM1 Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
Neoadjuvant Chemo/Pembro Betters pCR in Key ER+ Breast Cancer Subgroups
December 6th 2023Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.
Read More
ctDNA May Identify Risk of Recurrence in Early Breast Cancer Subgroup
December 6th 2023Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.
Read More
Capivasertib Shows Superior PROs Vs Placebo in HR+, HER2- Breast Cancer
December 6th 2023Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Read More
